PROPS (PET/MRI Pre-Radiotherapy for Post-Prostatectomy Salvage)
The PROPS trial is for men being considered for radiation therapy due to the suspicion that their
prostate cancer has recurred following the surgical removal of their prostate
(prostatectomy). This suspicion is based on rises seen on Prostate Specific Antigen (PSA)
blood tests. Only men who demonstrate the absence of disease on standard imaging scans
(Computed Tomography (CT) and bone scans) will be invited to participate.
This study will be assessing if the imaging probe 18-F Fluorocholine (18F-FCH) used during
Positron Emission Tomography (PET) and Magnetic Resonance Imaging (MRI) scans, can better
predict who will benefit from radiation therapy by identifying the source of cancer recurrence.
This will be determined by measuring the number of men who have disease identified outside
of the prostate bed (the small pocket or depression where the prostate used to be) on their
18F-FCH PET scan. Since F-18-FCH has been shown to be more sensitive in detecting prostate
cancer that may have spread into lymph nodes or bone, it may potentially identify areas of
prostate cancer spread not seen with standard imaging.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society